Continuous Peripheral Nerve Block Catheters Market: as the NOPAIN Act mandates separate Medicare reimbursement for non-opioid pain management devices, CPNB catheter placement shifts from a cost centre absorbed inside a bundled surgical payment into a separately billable clinical service, so ambulatory surgical centres gain a direct financial incentive to adopt ultrasound-guided regional anaesthesia, and vendors that pair catheter systems with AI-assisted ultrasound guidance are best placed to convert that incentive into procedure volume.

The global continuous peripheral nerve block catheters market size was USD 348.2 Million in 2025 and is expected to register a revenue CAGR of 5.1% during the forecast period. Market revenue growth is driven by factors such as the NOPAIN Act’s mandate for separate Medicare reimbursement of non-opioid pain management devices, ASRA-endorsed ultrasound-guided placement adoption in ambulatory surgical centres, and the emergence of AI-assisted ultrasound guidance software that lowers the skill barrier to regional anaesthesia placement. The first driving factor is the NOPAIN Act, which took effect for Medicare separate payment purposes in January 2025 and removed the financial disincentive that previously bundled CPNB catheter placement inside a single surgical payment. This reimbursement change gives ambulatory surgical centres a direct financial incentive to adopt non-opioid regional anaesthesia devices rather than absorbing their cost inside a fixed bundled payment. The second driving factor is the American Society of Regional Anesthesia and Pain Medicine’s endorsement of ultrasound-guided placement, which is associated with more accurate catheter positioning and lower complication rates than nerve stimulator-guided techniques. SmartAlpha’s Nerveblox AI-assisted ultrasound software received FDA 510(k) clearance in August 2025, helping physicians identify anatomical structures during ultrasound-guided regional anaesthesia procedures and lowering the training barrier that has historically limited adoption outside academic centres. The third driving factor is the maturation of ultrasound-guided regional anaesthesia as a standard technique embedded in ASRA clinical guidelines. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way NOPAIN Act reimbursement widens its own effect as more ambulatory surgical centres build billing infrastructure around separately payable non-opioid devices, letting each subsequent CPNB catheter placement convert more easily into reimbursed revenue without a new payer negotiation. Once an ambulatory surgical centre establishes billing and coding workflows for NOPAIN Act separate payment, every additional regional anaesthesia procedure benefits from that same infrastructure, so the value of the reimbursement pathway compounds as more centres complete their first billing cycle and normalise the process for subsequent cases. As a result, demand and revenue share are concentrating around catheter systems compatible with ultrasound guidance and separately reimbursable under the NOPAIN Act framework, and the forecast tilts toward ultrasound-compatible non-stimulating catheters rather than nerve stimulator-only systems. For instance, in August 2025, SmartAlpha, Turkey, received FDA 510(k) clearance for Nerveblox, its AI ultrasound guidance software, extending regulatory-cleared decision support to the placement step that determines whether a catheter procedure can be billed as a properly documented, image-guided regional anaesthesia service. These are some of the key factors driving revenue growth of the market.

The clearest driver of demand is the NOPAIN Act, which established separate Medicare reimbursement for qualifying non-opioid pain management devices used in ambulatory surgical centres. Separate payment works only if a device qualifies under the statute and a facility completes the billing and coding process to claim it, and this administrative step is what converts a previously cost-absorbing device into a revenue-generating one, so policy implementation and facility-level billing adoption move together. Prior to January 2025, CPNB catheter placement costs were typically absorbed inside a single bundled ambulatory surgical centre payment, creating a financial disincentive to use a device more expensive than a single-shot block regardless of its clinical benefit. The recent record shows the pace. ASRA-endorsed ultrasound-guided placement, now standard clinical guidance, positions ultrasound-compatible catheter systems as the default choice for centres building out NOPAIN Act-compliant billing workflows. The effect on the market is that ambulatory surgical centres now have a direct financial incentive, rather than only a clinical one, to adopt non-opioid regional anaesthesia devices. These are some of the key factors driving revenue growth of the market.

The second driver is the emergence of FDA-cleared AI software that assists less-specialised anaesthesiologists in performing ultrasound-guided nerve block placement. Ultrasound-guided placement requires recognising anatomical structures in real time, and this skill has historically taken years to develop, so AI tools that automate structure identification directly address the training bottleneck that has confined ultrasound-guided CPNB placement to academic centres. SmartAlpha received FDA 510(k) clearance in August 2025 for Nerveblox, an AI software solution that detects and highlights key anatomical structures during ultrasound-guided regional anaesthesia procedures, following earlier 2025 regulatory approvals in Europe, the UK, and Australia. The effect on the market is that community hospitals without dedicated regional anaesthesia fellowship-trained staff are gaining a viable pathway to adopt ultrasound-guided CPNB placement. These are some of the key factors driving revenue growth of the market.

“SmartAlpha’s Nerveblox, FDA-cleared in August 2025, detects and highlights key anatomical structures in real time during ultrasound-guided regional anaesthesia, directly addressing the specialist training bottleneck that has confined CPNB catheter placement to academic centres.”

The third driver is the migration of joint replacement and other orthopaedic procedures from inpatient hospital settings to ambulatory surgical centres. Same-day orthopaedic surgery requires effective post-operative pain control without the extended opioid use that would delay discharge, and continuous peripheral nerve block catheters directly address that requirement, so the shift to ambulatory orthopaedic surgery and CPNB catheter demand move together. Lower extremity surgeries, including total knee and hip arthroplasty, represent the largest indication category for CPNB catheters given the high procedure volume performed in ambulatory and hospital outpatient settings. The effect on the market is that CPNB catheter procedure volume is growing in step with the broader shift of orthopaedic surgery into ambulatory settings, independent of any single reimbursement policy change. These are some of the key factors driving revenue growth of the market.

However, the continuous peripheral nerve block catheters market faces severe adoption constraints from a limited supply of trained regional anaesthesia specialists in community hospitals, direct competition from single-shot nerve blocks, and the practical complexity of managing an outpatient infusion catheter. Because ultrasound-guided catheter placement requires specialised training that most community hospital anaesthesiology departments have not broadly developed, and because only a minority of catheter submissions have cleared FDA review on the standard timeline, adoption remains concentrated in academic orthopaedic centres with dedicated regional anaesthesia fellowship training regardless of the NOPAIN Act reimbursement incentive. Competition from single-shot nerve blocks is a second constraint, because a single-injection block delivers meaningful post-operative analgesia at a fraction of the cost, placement time, and follow-up complexity of a continuous catheter system, so many surgeons and anaesthesiologists default to single-shot blocks unless a specific indication, such as major joint reconstruction, favours extended infusion. Catheter and pump management complexity is the third constraint, since outpatient CPNB catheters require patient education on pump operation, monitoring for catheter dislodgement, and a defined follow-up pathway for catheter removal, and not every ambulatory surgical centre is staffed to reliably support this follow-up burden, so the cost of catheter-related complications is not always recovered through the procedure’s reimbursement. These factors substantially limit continuous peripheral nerve block catheters market growth over the forecast period.

Based on product type, the global continuous peripheral nerve block catheters market is segmented into non-stimulating catheters, stimulating catheters, and elastomeric and electronic infusion pumps. Non-stimulating catheters hold the largest revenue share, because they offer streamlined workflows compatible with ultrasound-only guidance, which suits the ASRA-endorsed shift toward ultrasound-guided placement over nerve stimulator techniques. Stimulating catheters remain established where ultrasound visualisation is technically difficult, and they provide a confirmatory electrical signal, but they cannot match the workflow speed of non-stimulating systems in routine ultrasound-guided placement. Elastomeric and electronic infusion pumps are expected to register rapid revenue growth in the global continuous peripheral nerve block catheters market over the forecast period, driven by growing outpatient use requiring portable, patient-controlled infusion, which is why pump manufacturers continue to integrate remote monitoring capability into ambulatory infusion systems.

Ultrasound-guided placement is expected to account for the largest revenue share in the global continuous peripheral nerve block catheters market during the forecast period

Based on insertion technique, the global continuous peripheral nerve block catheters market is segmented into ultrasound-guided and nerve stimulator-guided placement. Ultrasound-guided placement holds the largest revenue share, because it is associated with more accurate catheter positioning and lower complication rates, which suits ASRA clinical guidance and the growing use of ambulatory surgical centres for orthopaedic procedures. Ultrasound-guided placement is also expected to register the fastest revenue growth rate in the global continuous peripheral nerve block catheters market over the forecast period, driven by FDA-cleared AI guidance software such as SmartAlpha’s Nerveblox lowering the training barrier for community hospital adoption.

Based on indication, the global continuous peripheral nerve block catheters market is segmented into lower extremity, upper extremity, and truncal and abdominal surgery indications. Lower extremity surgeries hold the largest revenue share, reflecting the high volume of total knee and hip arthroplasty procedures performed in orthopaedic and ambulatory surgical settings, which suits the market’s concentration in academic orthopaedic centres. Upper extremity surgeries are expected to register rapid revenue growth in the global continuous peripheral nerve block catheters market over the forecast period, driven by growing outpatient shoulder arthroplasty and rotator cuff repair volumes, which is why interscalene brachial plexus catheter placement has become a growing area of clinical research.

Based on regional analysis, the continuous peripheral nerve block catheters market in North America accounted for largest revenue share in 2025. The United States leads because it is the sole jurisdiction implementing the NOPAIN Act’s separate Medicare reimbursement for non-opioid pain devices, and because B. Braun, Teleflex, and Avanos Medical, leading global regional anaesthesia device vendors, concentrate their commercial and regulatory activity in the country. SmartAlpha’s August 2025 FDA clearance for Nerveblox launched first into the United States ambulatory surgical centre market. The concentration of NOPAIN Act reimbursement infrastructure in the United States also means new ultrasound guidance and catheter technologies are typically adopted in the United States first.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, the United Kingdom, and France represent the three largest national CPNB catheter markets within Europe. B. Braun, headquartered in Germany, maintains deep installed relationships across European hospital anaesthesiology departments, and the region’s national health system reimbursement structures move more deliberately than the United States’ NOPAIN Act pathway. The result is steady rather than rapid growth, shaped more by established procurement cycles than by unmet clinical demand.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. Japan, China, and India represent the three largest national CPNB catheter markets within the region. Rising orthopaedic surgical volumes and expanding private hospital ambulatory surgical capacity in China and India are driving new regional anaesthesia device adoption from a comparatively lower installed base, leaving more room for growth than in the already-mature North America and Europe markets.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national CPNB catheter markets within the region. Private hospital networks in both countries are expanding regional anaesthesia capability, and the indirect effects of Iran-US sanctions and the associated Strait of Hormuz shipping disruption have kept freight and import costs elevated for the specialised catheter systems and ultrasound equipment that Latin American hospitals depend on through 2026, slowing adoption beyond the region’s main private hospital networks.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial CPNB catheter markets within the GCC. The UAE is the most established CPNB catheter market on the continent given its concentrated private hospital infrastructure, while the wider Gulf states and broader African markets are still building regional anaesthesia specialist capacity from scratch.